Microbix Biosystems Insider Trading
TSX MBX
12
All Trades
1
Significant
1
Notable
6
Clusters
10
Repeat
Healthcare
Sector
Biotechnology
Industry
$39.2M
Market Cap
0.21 – 0.32
52 Week Range
45K
Avg. Volume
| Company | Insider | Title | Tr. Date | Fi. Date | Shares | Price | Value | Balance | Increase | Signal |
|---|---|---|---|---|---|---|---|---|---|---|
| Microbix Biosystems | Groome, Cameron | CEO | 23-Jul-26 | 27-Jul-26 | 1,770,500 | MN RP | ||||
| Microbix Biosystems | Groome, Cameron | CEO | 30-Jun-26 | 30-Jun-26 | 1,770,000 | MN RP | ||||
| Microbix Biosystems | Costa, Daniel | R&D Scientist | 15-Jun-26 | 19-Jun-26 | 255,000 | MN CL RP | ||||
| Microbix Biosystems | Groome, Cameron | CEO | 17-Jun-26 | 18-Jun-26 | 1,758,000 | MN CL RP | ||||
| Microbix Biosystems | Groome, Cameron | CEO | 15-Jun-26 | 18-Jun-26 | 1,756,000 | MN CL RP | ||||
| Microbix Biosystems | Marino, Martin | Director | 28-May-26 | 28-May-26 | 2,000,167 | NT RP | ||||
| Microbix Biosystems | Marino, Martin | Director | 27-May-26 | 28-May-26 | 1,885,167 | MN RP | ||||
| Microbix Biosystems | Marino, Martin | Director | 26-May-26 | 28-May-26 | 1,860,667 | MN CL RP | ||||
| Microbix Biosystems | Costa, Daniel | R&D Scientist | 25-May-26 | 26-May-26 | 226,000 | MN CL RP | ||||
| Microbix Biosystems | Costa, Daniel | R&D Scientist | 22-May-26 | 26-May-26 | 225,500 | MN CL RP | ||||
| Microbix Biosystems | Marino, Martin | Director | 02-Jan-26 | 02-Jan-26 | 1,791,667 | MN | ||||
| Microbix Biosystems | Marino, Martin | Director | 22-Jan-25 | 28-Jan-25 | 1,540,000 | SI |
Microbix Biosystems (MBX): Insider trading △ Insider buy
Volume (thousands)
Related Companies to Explore
Company Info
Microbix Biosystems is a Canadian life science company that develops and sells biological and technological products for human health. The company operates across North America, Europe, and international markets. Its main focus is on producing biological materials and medical devices for the global diagnostics industry.
Microbix manufactures test ingredients, referred to as antigens, used in immunoassays and diagnostic testing. It also produces quality assessment and diagnostic test products sold under the QAPs brand, including test controls. Another product line is viral transport medium, sold under the DxTM brand, which is used to collect patient samples for pathogen testing, including the virus responsible for COVID-19. The company also manufactures Kinlytic, a biologic drug used to dissolve blood clots. In addition to these product lines, Microbix offers antigen products and provides vial filling services to customers.
The company operates within the healthcare sector, specifically in biotechnology. Its work spans both the tools used to develop and run diagnostic tests and a therapeutic drug product, making it active across more than one segment of the life sciences industry.
Don’t miss today’s trades
Full access to real-time insider buying data — $8.25/mo, billed annually. Cancel anytime.
